Small Dose Of Mip-1¦Á Joint Il-8 In Vitro Hematopoietic Stem / Progenitor Cells In The Protection Of Experimental Research

Objective: Study the protective effects of low dose macrophage inflammatory protein-i alpha ( MIP-1 a ) combined with interleukin-8 (IL-8) on hematopoietic stem/progenitor cells against the cytotoxicity of high dose chemotherapeutic drug Ara-C (8OmgIL) in vitro. Method: Bone marrow mononucleus cells were cultivated in liquid system contains IL-3 and GM-CSF. These cells were pretreated with MIP- 1 a and/or IL-8 in different concentration (1 ng/ml or 1 Ong/ml) for 24 hours, and then incubated with Ara-C (8OmgIL) for an addition 24 hours (we call these as first stage treatment). In order to know how about the proliferation of those cells after first stage treatment, the alive cells?number were counted after 7day抯 second liquid system culture and compaired with that of before second liquid system culture. Meantime, CFU-GM, CFU-E and CFU-Mix in 0.9% methyl cellulose system were numbered from third day to seventh day. In order to see how many CD34~ cells survived from the first stage treastment, the number of CD34~ cells were measured by FCM. At last, cell cycle were deterimined also by FCM so that we can detect the machinism of the protective effects of MIP- I a and IL-8 on hematopoietic stem/progenitor cells. Result: @ After first stage treatment, No matter under the concentration of I Ong/ml or 1 ng/ml, the numbers of alive cells among each group have no significent difference. ~ The number of viabilitive cells in second stage liquid system, the colony forming units of CFU-GM, CFU-E and CFU-Mix, and the number of CD34+ cells of MIP-1 a combined with IL-8 group in I Ong/ml concentration were significently higher than other groups (p<0.05),and there is no significent difference between other groups (p>0.05).On the other hand, there have any significent differences between all of the groups under concentration of Ing/ml (p>O.05). ?Cells in G0/G2 phase in the group treat with MIP-l a and IL-8 in concentration of I Ong/ml were lower than that of pretreat group (p0.05). Conclusion:~D MIP-1 a combined with IL-8 in concentration of Ing/ml have no positive protectoin on human hematopoietic stem/progenitor cells.? MIP- 1 a combined with IL-8 in concentration of 1 Ong/m] can protect human hematopoietic stem/progenitor cells against the cytotoxicity of high dose Ara-C in vitro.?MIP-1 a and IL-8 in concentration of 1 Ong/ml can inhibit CD34+ cells in G0/G1 phase.